The total order size is HKD 47 billion, and Jingtai Technology has set a new record for AI drug discovery cooperation orders

On August 5th, Jingtai Technology（2228.HK）Announced the completion of a pipeline cooperation contract with DoveTree with a total order size of approximately HKD 47 billion (USD 5.99 billion), and has received a down payment of approximately HKD 400 million (USD 51 million) as agreed in the agreement. According to the terms of the agreement, Jingtai Technology and DoveTree have reached a cooperation agreement on multiple large molecule and small molecule innovative drug assets in the preclinical stage, and will conduct new drug research and development for a series of DoveTree designated targets. DoveTree has exclusive global development and commercialization rights for related drugs. In return, in addition to the down payment, Jingtai Technology is entitled to receive further payments of approximately HKD 385 million (USD 49 million), as well as potential milestone payments and sales revenue of approximately HKD 46.2 billion (USD 5.89 billion).

This cooperation has set a new record for the scale of orders in the field of artificial intelligence (AI)+robot new drug research and development. DoveTree was founded by Dr. Gregory Verdine, a legendary entrepreneur in the biopharmaceutical industry. In this collaboration, both parties will deeply integrate Verdine's top biological mechanism research, target selection, and commercial development capabilities with Jingtai Technology's AI driven drug research and development technology advantages. The two companies will form a highly complementary advantage and jointly promote high potential pipeline projects in the fields of oncology, immune and inflammatory diseases, neurological diseases, and metabolic disorders. Verdine has rich successful experience in target selection and innovative drug development, with cumulative sales of three marketed drugs under its leadership exceeding billions of dollars. This cooperation not only confirms Jingtai Technology's expertise in AI driven drug research and developmentleadingThe technological strength also signifies the high recognition of the intelligent drug discovery model by the global biopharmaceutical industry, which is expected to accelerate the development process of innovative drugs and bring more clinically valuable treatment options to patients worldwide.

Biomedical 'strongest brain'

+AI platform creates a new paradigm for large-scale research and developmentformula

DoveTree is named after the Chinese national treasure Gongtong (commonly known as Pigeon Tree), aiming to integrate the advantages of drug research and development resources between China and the United States. By utilizing cutting-edge artificial intelligence technology and innovative research paradigms, combined with the basic scientific foundation of biology, DoveTree focuses on the development and clinical translation of the "first in class" (innovative new drug) pipeline in the field of major diseases, bringing new hope to patients. Founder Gregory Verdine is an internationally renowned entrepreneur, scientist, and senior investor in the field of biomedicine, with outstanding achievements in both academia and industry. Verdine has participated in the establishment of over ten biopharmaceutical companies, including Enanta Pharmaceuticals（NASDAQ: ENTA），Rein Therapeutics（NASDAQ: RNTX), WaVe Life Sciences（NASDAQ: WVE） Waiting for more than 5 listed companies. At the same time, as the proponent of the concept of "drug the undruggable", Verdine has innovatively developed a unique molecular gel and peptide technology platform, which has been successfully applied to the development of classic "undruggable" targets such as RAS, Myc, and β - catenin. Three of the drugs developed under his leadership have been approved for market by the FDA, and more than ten pipelines are currently in clinical development at different stages.

With the collaborative integration of advanced technologies such as generative AI and robot automation with basic sciences such as quantum physics and quantum chemistry, the pharmaceutical industry is building powerful algorithm tools and research and development capabilities at an unprecedented speed and accuracy. Verdine believes that AI has become a key technology for tackling innovative targets with research and development challenges, and Jingtai Technology's algorithms, computing power, and robotics technology are at the forefront of the AI pharmaceutical industry in terms of accuracy and scale. This collaboration will integrate Verdine's forward-looking insights and rich successful experience in target biology and drug development, as well as Jingtai Technology's "AI+robot automation" driven "0-1" new drug discovery platform capabilities. The pipeline cooperation between Jingtai Technology and DoveTree covers unmet clinical needs in the fields of tumors, immune and inflammatory diseases, neurological diseases, and metabolic disorders, and has significant market potential. At the same time, both parties also plan to jointly promote a series of new drug development projects targeting highly challenging or high-value targets selected by DoveTree in the future, and the specific plan is under further discussion.

According to Gregory Verdine, founder and CEO of DoveTree Medicine，I am deeply inspired by Jingtai Technology's technology platform and its demonstrated drug discovery capabilities. This technology system, which can achieve breakthroughs in drug innovation on a large scale, is gradually transforming the inherent uncertainty in the process of new drug development into predictable, quantifiable, and solvable engineering problems. This makes Jingtai Technology an extremely rare strategic partner and will have the opportunity to profoundly change the cooperation mode of drug discovery. The scale of our cooperation is groundbreaking, and it heralds the arrival of an era of new drug discovery deeply empowered by intelligent technology. DoveTree We will leverage the powerful platform advantages of Jingtai Technology, combined with our profound biological accumulation and mature drug research and development market and ecological resources in the United States, to develop a series of highly innovative drug pipelines and bring better and more efficient treatment options to patients worldwide as soon as possible. ”

Wen Shuhao, Chairman of the Board of Directors of Jingtai Technology, stated that，We always believe that the deep integration of artificial intelligence and robot automation technology will completely change the efficiency and success rate challenges of drug development, and bring key paradigm upgrades. Professor Gregory Verdine and DoveTree have rich experience in drug development success and precise market vision, which highly complement the platform capabilities of Jingtai Technology. This cooperation not only confirms the technological maturity of the platform, but also marks an innovative exploration in the research and development mode. We believe that the synergy of our strengths will accelerate breakthroughs in the development of challenging innovative targets and look forward to jointly pushing the future boundaries of AI driven drug research and development. Jingtai Technology will continue to consolidate its world leading underlying technology platform, work together with global innovation partners, and generate more rich and unique innovation pipelines from the source, creating value for the industry. ”

AI+robots break through data bottlenecks,

Building a source innovation engine for small and large molecules

As one of the few companies in the industry with both dry and wet research and development capabilities for small molecules, large molecules, antibody conjugated drugs (ADCs), and molecular gels, Jingtai Technology's AI drug development platform can effectively expand the space for drug development and has unique technological advantages. Jingtai Technology integrates quantum physics, artificial intelligence, and robot automation experimental verification to independently construct a complete end-to-end drug discovery solution, covering key research and development stages such as target validation, molecular generation, affinity prediction, ADMET property prediction, and synthesis route design. By establishing extensive cooperation with innovative pharmaceutical companies, their AI+robot driven R&D system has been validated in a wide range of real R&D projects, and has accumulated massive standardized experimental data and high-precision algorithm data, continuously driving model training and iterative upgrades.

In terms of target exploitability verification, Jingtai Technology integrates cutting-edge AI models, efficient sampling algorithms, and proprietary molecular dynamics simulation hardware, which can accelerate by more than 10 times and complete target protein conformation dynamics simulations that currently require more than three months for general methods within one week, greatly improving research efficiency; At the same time, by combining algorithms with cryo electron microscopy experiments, Jingtai Technology can reveal the dynamic changes of targets and their mechanisms of action with candidate compounds, thereby discovering new binding sites and conformational regulatory events, providing new design ideas for differentiated drug development.

InDrug activityIn terms of screening, Jingtai Technology has a high-precision affinity prediction model jointly developed with top global pharmaceutical companies and effectively validated by more than 100 targets. It can complete the affinity prediction of tens of thousands of compounds in a single day and significantly reduce computational costs, thereby achieving the conversion of "computing power as data" and driving AI models to explore new advantageous chemical spaces of drug like molecules more efficiently.

The compound with the highest priority for drug efficacy ranking after comprehensive algorithm evaluation will be synthesized and tested in the laboratory of hundreds of automated robot clusters at Jingtai Technology. Jingtai Technology has built a trillion level Make on demand compound library with high-precision chemical reaction prediction models, and can predict chemical synthesis paths, helping scientists bridge the gap from virtual design space to real physical space; Its intelligent autonomous experimental platform that combines dry and wet processes can efficiently synthesize and test thousands of AI generated compounds within a week, accurately collect targeted data for the research system, and provide feedback to molecular generation algorithms. This system can quickly accumulate initial data even when facing new targets and systems without prior data, and continuously optimize candidate drug molecules that better meet project requirements through efficient iterations, achieving an upgrade from an "experience driven" to a "data-driven" drug development model.

In terms of macromolecules, Jingtai Technology's AI powered macromolecular drug discovery platform integrates advanced AI algorithms and high-throughput experimental techniques, which can break through the limitations of traditional sequence space, quickly identify high potential antibody candidate molecules, and conduct structure based rational design and key property optimization, thereby significantly shortening the drug development cycle and accelerating the preclinical research process. Its XtalFold ® The platform is the world's first AI macromolecular drug structure modeling platform that has been fully validated in a large number of drug pipelines. It can generate high-precision protein complex structures based on sequences and has been validated by multiple international pharmaceutical companies, establishing platform authorization cooperation.

After signing the contract, Jingtai Technology plans to deepen cooperation with Dr. Verdine in the field of molecular glue research and development. At present, with the help of AI, molecular block library, automated synthesis, and high-throughput screening technology, Jingtai Technology has established a molecular gel research and development platform suitable for multiple targets and scenarios. It can predict potential molecular gel targets and explore a wider and more diverse molecular space, using chiral molecular blocks to obtain small molecule compounds with better drug properties. By collecting data and establishing an AI model for the automated synthesis reaction of molecular gels, Jingtai Technology can achieve multiple rounds of rapid iteration in the design and synthesis of compound libraries during the molecular gel discovery process, accelerating the discovery of molecular gel compounds.

●closeYuDoveTree●

DoveTree is an innovative biopharmaceutical company that develops a high-value first in class pipeline for unmet clinical needs in serious and chronic diseases such as autoimmune, cancer, and neurological disorders based on next-generation biological mechanisms. DoveTree is named after the ancient rare plant species, Gongtong (also known as Pigeon Tree), unique to Yunnan, China. It aims to integrate the thriving research and development ecosystem of the United States with the well-developed pharmaceutical market, as well as China's emerging cutting-edge research and development platforms and innovative pipeline assets, like the beautiful and lush "Pigeon Tree", to bring new hope to human health.